SPOTLIGHT: FDA committee to review ADHD risks
An FDA committee is scheduled to meet in a week to review how the agency should best study the cardiovascular risks posed by ADHD drugs. Concerns were heightened by Canada's decision to pull Adderall XR from the market last year. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
